Could THIS be your biggest trading advantage?

Hey there, bargain hunter. Cerebras Systems (CBRS) reports Q3 Thursday after the close. The stock near $94 is about 49% below its May IPO price of $185. The question is whether that crash created an entry point or just a cheaper problem.

Scoreboard

CBRS has traded as low as $77.84 this year. At $94, the market cap is roughly $20 billion, priced above 22x forward sales. Analysts expect Q3 core revenue of $214.7 million and a loss of $0.14 per share. Cloud revenue surged 287% in Q2 to $127.7 million. That is the number carrying the entire bull case.

Why the Stock Fell

Two things hit at once. Core gross margin dropped from 46.5% in Q1 to 40.6% in Q2, as Cerebras rented hardware back from customers to cover inference demand faster than its owned capacity allowed. Management guided Q3 to 38-40%, calling it the trough before owned systems push margins toward 60% plus.

Then on October 28, short seller Culper Research alleged the wafer-scale chips last only 1.5 to 2.5 years in the field. Using a 2.25-year useful-life assumption, Culper put first-half 2026 gross margin at 24.0% against the 29.9% Cerebras reported on a GAAP basis. The allegations are unverified. They arrived alongside a lockup expiration covering 19.4 million shares.

Short-seller pressure and lockup expirations are not unique to Cerebras. CoreWeave carries its own version of customer concentration risk and backlog-versus-revenue tension that AI cloud investors keep underpricing.

The Business

Cerebras builds the Wafer Scale Engine, a processor the size of an entire silicon wafer. The company claims 2,625 times more memory bandwidth than Nvidia’s B200 package and inference speeds up to 15 times faster on leading open-source models. Revenue splits between hardware and cloud-based inference. Cloud grew 232% in H1 2026.

What Matters Thursday

• Q3 core revenue guide: $214-216 million
• Q3 gross margin: guided 38-40%, stated trough
• FY2026 raised guidance: $880-890 million, 41-43% gross margin
• Remaining performance obligations: $25.4 billion at June 30
• Liquidity: $7.4 billion cash, cash equivalents, and restricted cash, plus $1.2 billion of marketable securities
• Top customer concentration: 49% of H1 revenue, up from 47% a year ago

Is It Cheap?

Not yet. At 22x forward sales, every dollar of conviction rides on 2027 core revenue tripling to around $2.77 billion. If it does, the multiple compresses sharply. If margins are structurally lower than reported due to chip life assumptions, the 60% plus gross margin target moves further out.

Bull / Base / Bear

Bull: Q3 margin lands at 40%, Q4 guide confirms recovery, OpenAI ramp holds. Analyst consensus targets near $266 pull the stock higher.

Base: Trough confirmed but recovery is slower. Revenue scales; margins stall in the 50% range. Partial recovery.

Bear: Culper allegations gain traction, margin assumptions reset, OpenAI concentration stalls. Stock retests $77.

Action Plan

Wait for the Thursday call. Listen for two things: a Q4 margin guide above 43%, and management addressing the chip lifespan claims directly. Neither has appeared yet. Without both, 22x sales is hard to own.

Cheap Investor Checklist

• Q3 gross margin: at or above 38-40% guide?
• Q4 guidance: does it quantify the recovery?
• Culper rebuttal: direct response or silence?
• Top customer share: below 40% of Q3 revenue?
• RPO: does $25.4 billion hold or expand?

Bottom Line

If Q4 guidance confirms the margin turn and management rebuts the durability claims with data, bargain hunters with a two-year horizon have a real argument at $94. If Thursday sidesteps both, there is no cushion in a 22x sales multiple. The report does not need to be great. It needs to prove the margin story is not broken.